Please assess the completion status of the following clinical trial:

Trial Title: A Study of KRN23 in X-linked Hypophosphatemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years or older~2. Clinical diagnosis of XLH~3. TmP/GFR is less than 2.0 mg/dL~4. GFR is 60 mL/min or above~Exclusion Criteria:~1. Have any sign of active infectious disease or have had an infection requiring treatment with antibiotics within three weeks prior to screening~2. History of known immunodeficiency~3. Lactating females, female patients who are pregnant or planning to become pregnant during the study~4. Use of a pharmacologic vitamin D metabolite or its analog, phosphate, calcimimetics, and ingestion of aluminum hydroxide antacids within 10 days prior to screening and dosing~5. Use of any supplement contained phosphate, calcium and/or vitamin D within 10 days prior to screening and dosing~6. Receipt of live (attenuated) vaccine within 3-months prior to screening~7. Have any condition which, in the opinion of the Investigator, could present a concern for either patient safety or difficulty with data interpretation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KRN23 (Type: EXPERIMENTAL): Single IV or SC administration on day 1
- Placebo (Type: PLACEBO_COMPARATOR): Single IV or SC administration on day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).